DHCR7-DT and systemic lupus erythematosus: Furthermore, Sekine et al. reported the benefit of the selective inhibition of the AP for renal disease in lupus-prone MRL/lpr and NZM2410 mice by therapeutic administration of a targeted and selective inhibitor of the AP CR2-fH, compared to CR2-Crry, which inhibits all complement pathways (20, 21).